ADA Position Statement 2017 – Διαβήτης και Υπέρταση
Το νέο Position Statement για τον Σακχ. Διαβήτη και την Αρτ. Υπέρταση της Αμερικανικής Διαβητολογικής Εταιρείας (ADA) »»
Hypertension is common among patients with diabetes, with the prevalence depending on type and duration of diabetes, age, sex, race/ethnicity, BMI, history of glycemic control, and the presence of kidney disease, among other factors. Furthermore, hypertension is a strong risk factor for atherosclerotic cardiovascular disease (ASCVD), heart failure, and microvascular complications. ASCVD—defined as acute coronary syndrome, myocardial infarction (MI), angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin—is the leading cause of morbidity and mortality for individuals with diabetes and is the largest contributor to the direct and indirect costs of diabetes. Numerous studies have shown that antihypertensive therapy reduces ASCVD events, heart failure, and microvascular complications in people with diabetes. Large benefits are seen when multiple risk factors are addressed simultaneously. There is evidence that ASCVD morbidity and mortality have decreased for people with diabetes since 1990 likely due in large part to improvements in blood pressure control. This Position Statement is intended to update the assessment and treatment of hypertension among people with diabetes, including advances in care since the American Diabetes Association (ADA) last published a Position Statement on this topic in 2003.
Ειδικός Παθολόγος – Διαβητολόγος